NCT04422678

The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia

Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia: A Pilot Study

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.

Detailed description

As the coronavirus disease (COVID-19) spreads worldwide, awaiting the development of a vaccine, researchers are looking among the arsenal of available drugs, for a potential cure or medication to improve patients' outcome. A highly elevated levels of cytokines in COVID-19 patients requiring ICU admission, has suggested that a "cytokine storm" was associated with disease severity. Data from cellular, animal models and clinical trials, showed a beneficial role of tyrosine kinase inhibitors in the regulation of inflammation, the maintenance of endothelial barrier integrity, as well as the expression of antiviral properties. This data is especially derived from imatinib, the most studied Abl family kinase inhibitor, that is currently in clinical use for multiple medical conditions. Based on this encouraging data, we hypothesize that imatinib might be beneficial for the treatment of patients with SARS-CoV-2 pneumonia, in the aim of preventing disease progression into the severe phenotype of hypoxic respiratory failure and acute respiratory distress syndrome.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Imatinib Mesylate	Adding treatment by imatinib oral tablet into the standard treatment for moderate to severe COVID-19 pneumonia.
DRUG	Standard of Care	Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.

Timeline

• Start date: 2020-06-01
• Primary completion: 2020-09-01
• Completion: 2020-10-01
• First posted: 2020-06-09
• Last updated: 2020-06-09